Introduction

In July 2025, the FDA took a significant step toward regulatory transparency by consolidating over 200 redacted Complete Response Letters (CRLs) for drug and biologic applications submitted between 2020 and 2024. Notably, at least 14 of these documents were previously unavailable to the public and have now been released for the first time. These newly accessible documents, found on openFDA, offer invaluable insights into the most common causes of regulatory delays, providing sponsors with a clearer roadmap to avoid them.

At Lumanity, our Clinical & Regulatory team conducted an in-depth analysis of these CRLs to better understand the recurring themes driving initial FDA rejections. Our findings are clear: most issues are not unexpected or novel. Instead, they stem from a consistent set of missteps, many of which are entirely avoidable with proactive planning, strong cross-functional alignment, and the right expertise.

This article summarizes five key findings from our analysis and provides strategic recommendations to help sponsors strengthen their regulatory readiness and significantly increase the likelihood of first-cycle approval.

1. Inspection Readiness Remains a Top Risk

What This Means for Sponsors

The majority of CRLs cited manufacturing-related issues, particularly unresolved Form 483 observations or pre-approval inspection (PAI) failures. Whether related to internal manufacturing facilities or third-party Contract Manufacturing Organizations (CMOs), gaps in quality systems, documentation, or facility readiness continue to be one of the most common—and costly—reasons for regulatory delays.

Recommended Actions

  • Initiate mock inspections and independent GMP audits well in advance of your submission. This proactive approach helps identify and address deficiencies before they become critical issues.
  • Address known quality system deficiencies proactively. Don’t wait for the FDA to find them; implement robust corrective and preventive actions immediately.
  • Integrate CMC and regulatory planning across all global manufacturing sites. A unified strategy ensures consistency and compliance worldwide.

2. Clinical Data Must Be Clear, Complete, and Defensible

Implications for Development Strategy

Many CRLs highlighted concerns about unclear dose-response relationships, insufficient exposure or PK/PD data, and unresolved long-term safety questions. In some instances, efficacy was established, but the broader clinical picture lacked the clarity or coherence that FDA reviewers expect for a comprehensive assessment.

Recommended Actions

  • Align study designs with FDA expectations regarding dosing, exposure, and safety thresholds from the outset.
  • Prioritize endpoint selection and justification during protocol development. Ensure your chosen endpoints are robust and clearly support your claims.
  • Utilize exposure-response modeling and population PK analysis to thoroughly bolster comparability and provide a strong data-driven narrative.

3. Labeling and Human Factors Are Commonly Overlooked

Key Takeaway

Applications were frequently delayed due to avoidable issues such as incomplete labeling strategies, unvetted proprietary names, or user-related safety concerns with drug-device combinations. These challenges often emerge late in development, leading to significant and often preventable delays in review timelines.

Recommended Actions

  • Begin labeling strategy and proprietary name clearance early in the development process. This allows ample time for review and adjustment.
  • Conduct thorough human factors assessments for combination products or complex administration routes to ensure safe and effective use.
  • Integrate regulatory usability review into your development milestones to catch and correct issues before they impact submission.

4. FDA Engagement Must Be Proactive and Coordinated

Why This Matters

Many CRLs reflected communication gaps between sponsors and the FDA. Missed opportunities to engage reviewers during crucial development stages, particularly pre-NDA/BLA meetings, often led to misunderstandings or unresolved concerns that could have been effectively mitigated earlier in the process.

Recommended Actions

  • Develop a comprehensive engagement plan from pre-IND to submission. Map out key interactions and their objectives.
  • Utilize Type C and pre-submission meetings to confirm expectations and clarify any ambiguities directly with the agency.
  • Maintain consistent documentation and diligent follow-up on all reviewer feedback to ensure all concerns are addressed.

5. Resubmissions Must Be Strategic and Complete

Best Practices for Resubmission

In several cases, incomplete or miscategorized responses (e.g., labeling a resubmission as an “amendment”) led to additional review cycles. Responses that failed to address each deficiency thoroughly or clearly only prolonged delays.

Recommended Actions

  • Treat resubmissions with the same rigor and strategic planning as your original application. It’s not just an administrative fix.
  • Follow FDA format and content expectations precisely. Adherence to guidelines is crucial for efficient review.
  • Prepare detailed crosswalks that meticulously map each deficiency cited in the CRL to your specific response, demonstrating comprehensive resolution.

Strategic Recommendations for Sponsors

To consistently avoid CRLs and stay on the most direct path to regulatory success, sponsors should:

  • Plan for inspection readiness early in development, integrating quality considerations from the outset.
  • Design clinical programs with robust safety, exposure, and PK/PD rationale that fully address potential FDA concerns.
  • Begin labeling and human factors planning well before submission, making them integral parts of your development timeline.
  • Engage the FDA early and maintain open, consistent communication throughout the development lifecycle.
  • Treat resubmissions as a strategic opportunity, not an administrative fix, ensuring thorough and compliant responses.

Why Preventing CRLs Should Be a Strategic Priority

A Complete Response Letter is far more than a simple delay; it’s a significant disruption. It can halt commercialization plans, necessitate additional costly studies, increase operational expenses, and, most importantly, delay patient access to critical therapies. Furthermore, a CRL can erode stakeholder confidence and weaken hard-won market momentum.

The good news is that most CRLs are avoidable. The most common issues—quality system gaps, misaligned clinical data, usability oversights, and missed communication opportunities—can be effectively addressed with the right expertise, through better planning, deeper integration of regulatory strategy, and early, cross-functional execution.

Ready to Avoid Regulatory Setbacks?

Whether you’re preparing for an upcoming FDA submission, recovering from a CRL, or just beginning to conceptualize the research-to-development transition for a new program, Lumanity offers the insight, experience, and expertise you need. We help you stay ahead, confidently progressing toward your goals.

Let’s build your path to approval—faster, smarter, and with fewer roadblocks.

Contact Katie McCarthy at Katie.McCarthy@Lumanity.com to learn more.

About Lumanity

At Lumanity, we empower life science companies to navigate the complexities of product development with confidence and clarity. Our Clinical & Regulatory team brings deep, integrated expertise across regulatory, quality, and clinical development.

By integrating insights across the entire development lifecycle, we help sponsors:

  • Anticipate regulatory challenges before they escalate into costly delays.
  • Craft development strategies that support both long-term regulatory and commercial success.
  • Build submission packages precisely aligned with FDA expectations to achieve first-cycle approval with fewer surprises.